Prolaio Inc.

Prolaio Inc. is an FDA-cleared software platform designed to unite patients, care teams, and clinical researchers in cardiology through secure, technology-enabled data collection and analysis. The company develops real-world clinical data solutions specifically focused on heart disease management and drug development acceleration. Prolaio's platform collects continuous, high-density on-body patient data and applies advanced machine learning algorithms to synthesize meaningful clinical insights for treatment decisions and research optimization. The platform serves three primary user groups: patients receiving continuous heart health monitoring integrated with their care teams, care teams making longitudinal treatment decisions based on synthesized clinical data, and clinical researchers seeking high-density datasets to optimize study design and reduce trial overhead. The company has developed 40+ proven algorithms with 5 FDA-cleared algorithms currently deployed. Prolaio has accumulated over 4 million hours of on-body patient data across operations in 26+ countries. The company holds 20+ issued patents in machine learning and clinical data analytics. With 30+ years of cumulative machine learning expertise embedded in its platform, Prolaio addresses the significant clinical and economic burden of heart disease—the leading cause of death in the United States and responsible for 1.3 million preventable hospitalizations annually. The platform is designed to accelerate cardiology breakthroughs, improve patient outcomes, and streamline clinical research workflows by providing actionable, real-world clinical intelligence.